Hadassah

Collaboration Announced to Develop Hadassah Drug to Treat “Untreatable” NASH Liver Disease

Friday, Aug 5 2016

Hadasit, the Hadassah Medical Organization’s technology transfer company, has signed an agreement with BioLineRx Ltd. to develop a drug to treat non-alcoholic steatohepatitis (NASH), based on the pre-clinical work of Hadassah’s Prof. Rifaat Safadi, head of its Liver Unit. Currently, there are no Federal Drug Administration-approved treatments for NASH.

NASH is the progressive form of non-alcoholic fatty liver disease (NAFLD) and, in many cases, leads to cirrhosis of the liver and, ultimately, liver cancer. This “in-licensing agreement” represents a partnership between two companies with shared intentions, goals, and fields of interest. "Under the collaboration,” explains Dr. Kinneret Savitsky, Chief Executive Officer of BioLineRx,” Novartis will provide us with valuable professional advice and consultancy throughout the development process. This project fits our strategic focus on the immunology space, since it works through modulation of the immune system.”

The drug candidate, to be called BL-1210, offers a novel mechanism for controlling liver fibrosis, the scarring process that represents the liver's response to injury. When scar tissue builds up and takes over most of the liver, cirrhosis is the result. By modulating the immune system, the drug would reduce scarring and control the disease’s progression.

As Hadasit explains about the Hadassah Medical Center on its website, “The combination of practical experience, the ability to pinpoint medical needs, and cutting-edge research has yielded a huge potential for ideas, innovation, and developments in all aspects of medicine, including therapeutics, diagnostics, and medical devices. Founded in 1986, Hadasit has been investing in turning ideas into viable products and services for the benefit of humanity.”

Comments

From: Michelle on August 25, 2016
I was first diagnosed with NASH in 2003. Nobody I knew had ever heard of NASH. At the beginning even some of my doctors, often were unknowldgeable on NASH. I was their key to unlock the information vault. I am willing to be a test subject.
First Name
Email
Comment
Enter this word:

Related Stories

alt_text

Thursday, Sep 14 2017

Hadassah's Head of Emergency Medicine Springs to Action at Bar Mitzvah

Dr. Jacob (Koby) Assaf, head of Emergency Medicine at Hadassah Hospital Ein Kerem, was at a family Bar Mitzvah in a Jerusalem hotel when suddenly a 60-year-old man collapsed right next to him.

READ MORE ›
alt_text

Thursday, Sep 14 2017

Professor, Grandfather, and Cancer Survivor: A Hadassah Story

Following a consultation with Hadassah Endocrinologist and NET specialist Dr. Simona Glasberg, Prof. Bruins underwent numerous tests to determine the source and extent of penetration of this slow-developing type of cancer.

READ MORE ›
alt_text

Thursday, Sep 7 2017

Upgraded Sperm Bank Inaugurated at Hadassah-Mt. Scopus

A spacious, upgraded sperm bank and new laboratories have been inaugurated at Hadassah Hospital Mount Scopus.

READ MORE ›
alt_text

Thursday, Sep 7 2017

Study by Renowned Hadassah Neuropsychiatrist Featured in The Lancet

The work of Dr. Shahar Arzy, head of the Hadassah Medical Organization’s Neuropsychiatry Clinic and the Hadassah-Hebrew University Computational Neuropsychiatry Laboratory, is featured in the September 4, 2017 issue of The Lancet Psychiatry.

READ MORE ›

Donation Questions

donorservices@hadassah.org

(800) 928-0685

Membership Questions

membership@hadassah.org

(800) 664-5646

Missions Department

missions@hadassah.org

(800) 237-1517

Contact Us

40 Wall Street

New York, NY 10005

support@hadassah.org

More ›

Show More